Abstract:Pathogenic variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified that increase the risk for developing Parkinson's disease in a dominantly inherited fashion. These pathogenic variants, of which G2019S is the most common, cause abnormally high kinase activity, and compounds that inhibit this activity are being pursued as potentially disease-modifying therapeutics. Because LRRK2 regulates important cellular processes, developing inhibitors that can selectively target the pathogenic variant while sparing normal LRRK2 activity could offer potential advantages in heterozygous carriers. We conducted a high-throughput screen and identified a single selective compound that preferentially inhibited G2019S-LRRK2. Optimization of this scaffold led to a series of novel, potent, and highly selective G2019S-LRRK2 inhibitors.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01243?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01243</a>.Compound 1 homology model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_001.pdb">PDB</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_002.csv">CSV</a>)Kinase panel for compound 31 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_003.csv">CSV</a>)Crystal data for compound (R)-32; 1H NMR and HPLC traces for compounds 1, 4, 7, 19, 20, 21, 22, 23, 25, 26, 30, and 31; and table of geometric mean and geometric standard deviation of biochemical potency (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_004.pdf">PDF</a>)This article has not yet been cited by other publications.

Characterization of a Selective Inhibitor of the Parkinson’s Disease Kinase LRRK2

Type-II kinase inhibitors that target Parkinson’s Disease-associated LRRK2

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease

Brain Penetrant LRRK2 Inhibitor.

Discovery of potent LRRK2 inhibitors by ensemble virtual screening strategy and bioactivity evaluation

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Recent Advances in Targeting Leucine-Rich Repeat Kinase 2 As a Potential Strategy for the Treatment of Parkinson's Disease.

Single molecule array measures of LRRK2 kinase activity in serum link Parkinson's disease severity to peripheral inflammation

Unveiling the Selectivity Mechanism of Type-I LRRK2 Inhibitors by Computational Methods: Insights from Binding Thermodynamics and Kinetics Simulation.

Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives

Selective Inhibitors of G2019S-LRRK2 Kinase Activity

Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease

Leucine-rich Repeat Kinase 2 Inhibitors: a Patent Review (2006 – 2011)

Leucine-rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule-associated protein 1B to ameliorate lysosomal dysfunction and parkinsonism

Identification of LRRK2 Inhibitors Through Computational Drug Repurposing.

Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.

LDN-73794 Attenuated LRRK2-Induced Degeneration in a Drosophila Parkinson’s Disease Model

Leucine-Rich Repeat Kinases

Molecular Modeling Study on the Interaction Mechanism Between the LRRK2 G2019S Mutant and Type I Inhibitors by Integrating Molecular Dynamics Simulation, Binding Free Energy Calculations, and Pharmacophore Modeling.

Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission

GSK 2578215 A ; A Potent and Highly Selective 2-Arylmethyloxy-5-substitutent-n-arylbenzamide LRRK 2 Kinase Inhibitor